カテゴリー： Market Monitor Global, 世界, 医療/バイオ

脊髄性筋萎縮症治療の世界市場見通し2023年-2029年

◆英語タイトル：Spinal Muscular Atrophy Medicine Market, Global Outlook and Forecast 2023-2029
	◆商品コード：MMG23LY8679 ◆発行会社（リサーチ会社）：Market Monitor Global ◆発行日：2023年7月 ◆ページ数：116 ◆レポート形式：英語 / PDF ◆納品方法：Eメール（受注後2-3営業日） ◆調査対象地域：グローバル ◆産業分野：医薬品＆ヘルスケア

◆販売価格オプション（消費税別）

Single User（1名様閲覧用）	USD3,250 ⇒換算￥494,000	見積依頼/購入/質問フォーム
Multi User（20名様閲覧用）	USD4,225 ⇒換算￥642,200	見積依頼/購入/質問フォーム
Enterprise User（閲覧人数制限なし）	USD4,875 ⇒換算￥741,000	見積依頼/購入/質問フォーム

★Market Monitor Globalに受託調査の見積を依頼する

※販売価格オプションの説明はこちらで、ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※Eメールによる納品の場合、通常ご注文当日～2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行・送付致します。（請求書発行日より2ヶ月以内の銀行振込条件、カード払いに変更可）
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。

❖ レポートの概要 ❖

Global Spinal Muscular Atrophy Medicine Market 調査レポートは次の情報を含め、グローバルにおけるの脊髄性筋萎縮症治療市場規模と予測を収録しています。・世界の脊髄性筋萎縮症治療市場：売上、2018年-2023年、2024年-2029年
・世界の脊髄性筋萎縮症治療市場：販売量、2018年-2023年、2024年-2029年
・世界のトップ5企業、2022年

世界の脊髄性筋萎縮症治療市場は2022年に000Mドルと評価され、予測期間中に000％のCAGRで2029年までに000Mドルに達すると予測されています。アメリカ市場は2022年に000Mドルと推定されており、中国は2029年までに000Mドルに達すると予測されています。「LMI-070」セグメントは今後6年間、000%の年平均成長率で2029年までに000Mドルに成長すると予測されています。

脊髄性筋萎縮症治療のグローバル主要企業は、Astellas Pharma Inc.、 AveXis, Inc.、 Bioblast Pharma Ltd.、 Cytokinetics, Inc. 24、 F. Hoffmann-La Roche Ltd.、 Genethon、 Genzyme Corporation、 GMP-Orphan SAS、 Ionis Pharmaceuticals, Inc.、 Longevity Biotech, Inc、 Neurodyn Inc.、 Neurotune AG、 Novartis AG、 Sarepta Therapeutics, Inc.、 Voyager Therapeutics, Inc.、 Vybion, Inc.、 WAVE Life Sciences Ltd.などです。2022年にトップ5企業がグローバル売上シェアの約000%を占めています。

マーケットモニターグローバル社は、脊髄性筋萎縮症治療のメーカー、サプライヤー、流通業者、および業界の専門家を調査しました。これには、販売量、売上、需要、価格変動、製品タイプ、最近の動向と計画、産業トレンド、成長要因、課題、阻害要因、潜在的なリスクなどが含まれます。

【セグメント別マーケット分析】

世界の脊髄性筋萎縮症治療市場：タイプ別、2018年-2023年、2024年-2029年
世界の脊髄性筋萎縮症治療市場：タイプ別市場シェア、2022年
・LMI-070、ND-602、NT-1654、ヌシネルセン、NXD-30001、その他

世界の脊髄性筋萎縮症治療市場：用途別、2018年-2023年、2024年-2029年
世界の脊髄性筋萎縮症治療市場：用途別市場シェア、2022年
・病院、クリニック、その他

世界の脊髄性筋萎縮症治療市場：地域・国別、2018年-2023年、2024年-2029年
世界の脊髄性筋萎縮症治療市場：地域別市場シェア、2022年
・北米：アメリカ、カナダ、メキシコ
・ヨーロッパ：ドイツ、フランス、イギリス、イタリア、ロシア
・アジア：中国、日本、韓国、東南アジア、インド
・南米：ブラジル、アルゼンチン
・中東・アフリカ：トルコ、イスラエル、サウジアラビア、UAE

【競争分析】

また、当レポートは主要な参入企業の分析を提供します。
・主要企業における脊髄性筋萎縮症治療のグローバル売上、2018年-2023年
・主要企業における脊髄性筋萎縮症治療のグローバル売上シェア、2022年
・主要企業における脊髄性筋萎縮症治療のグローバル販売量、2018年-2023年
・主要企業における脊髄性筋萎縮症治療のグローバル販売量シェア、2022年

さらに、当レポートは主要企業の情報を提示します。
Astellas Pharma Inc.、 AveXis, Inc.、 Bioblast Pharma Ltd.、 Cytokinetics, Inc. 24、 F. Hoffmann-La Roche Ltd.、 Genethon、 Genzyme Corporation、 GMP-Orphan SAS、 Ionis Pharmaceuticals, Inc.、 Longevity Biotech, Inc、 Neurodyn Inc.、 Neurotune AG、 Novartis AG、 Sarepta Therapeutics, Inc.、 Voyager Therapeutics, Inc.、 Vybion, Inc.、 WAVE Life Sciences Ltd.

*************************************************************

・調査・分析レポートの概要
脊髄性筋萎縮症治療市場の定義
市場セグメント
世界の脊髄性筋萎縮症治療市場概要
当レポートの特徴・ベネフィット
調査手法と情報源

・世界の脊髄性筋萎縮症治療市場規模
世界の脊髄性筋萎縮症治療市場規模：2022年 VS 2029年
世界の脊髄性筋萎縮症治療市場規模と予測 2018年-2029年

・競争状況
グローバルトップ企業
売上ベースでのグローバルトップ企業
企業別グローバルでの脊髄性筋萎縮症治療の売上
グローバルトップ3およびトップ5企業、2022年売上ベース
グローバル企業の脊髄性筋萎縮症治療製品タイプ
グローバルにおけるティア1、ティア2、ティア3企業

・タイプ別市場分析
タイプ区分：LMI-070、ND-602、NT-1654、ヌシネルセン、NXD-30001、その他
脊髄性筋萎縮症治療のタイプ別グローバル売上・予測

・用途別市場分析
用途区分：病院、クリニック、その他
脊髄性筋萎縮症治療の用途別グローバル売上・予測

・地域別市場分析
地域別脊髄性筋萎縮症治療市場規模 2022年と2029年
地域別脊髄性筋萎縮症治療売上・予測
北米市場：アメリカ、カナダ、メキシコ
ヨーロッパ市場：ドイツ、フランス、イギリス、イタリア、ロシア
アジア市場：中国、日本、韓国、東南アジア、インド
南米市場：ブラジル、アルゼンチン
中東・アフリカ市場：トルコ、イスラエル、サウジアラビア、UAE

・主要企業の情報（企業概要、事業概要、主要製品、売上、ニュースなど）
Astellas Pharma Inc.、 AveXis, Inc.、 Bioblast Pharma Ltd.、 Cytokinetics, Inc. 24、 F. Hoffmann-La Roche Ltd.、 Genethon、 Genzyme Corporation、 GMP-Orphan SAS、 Ionis Pharmaceuticals, Inc.、 Longevity Biotech, Inc、 Neurodyn Inc.、 Neurotune AG、 Novartis AG、 Sarepta Therapeutics, Inc.、 Voyager Therapeutics, Inc.、 Vybion, Inc.、 WAVE Life Sciences Ltd.
...

This report aims to provide a comprehensive presentation of the global market for Spinal Muscular Atrophy Medicine, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Spinal Muscular Atrophy Medicine. This report contains market size and forecasts of Spinal Muscular Atrophy Medicine in global, including the following market information:
Global Spinal Muscular Atrophy Medicine Market Revenue, 2018-2023, 2024-2029, ($ millions)
Global Spinal Muscular Atrophy Medicine Market Sales, 2018-2023, 2024-2029, (K Pcs)
Global top five Spinal Muscular Atrophy Medicine companies in 2022 (%)
The global Spinal Muscular Atrophy Medicine market was valued at US$ million in 2022 and is projected to reach US$ million by 2029, at a CAGR of % during the forecast period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
The U.S. Market is Estimated at $ Million in 2022, While China is Forecast to Reach $ Million.
LMI-070 Segment to Reach $ Million by 2029, with a % CAGR in next six years.
The global key manufacturers of Spinal Muscular Atrophy Medicine include Astellas Pharma Inc., AveXis, Inc., Bioblast Pharma Ltd., Cytokinetics, Inc. 24, F. Hoffmann-La Roche Ltd., Genethon, Genzyme Corporation, GMP-Orphan SAS and Ionis Pharmaceuticals, Inc., etc. in 2022, the global top five players have a share approximately % in terms of revenue.
MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Spinal Muscular Atrophy Medicine manufacturers, suppliers, distributors and industry experts on this industry, involving the sales, revenue, demand, price change, product type, recent development and plan, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Spinal Muscular Atrophy Medicine Market, by Type, 2018-2023, 2024-2029 ($ Millions) & (K Pcs)
Global Spinal Muscular Atrophy Medicine Market Segment Percentages, by Type, 2022 (%)
LMI-070
ND-602
NT-1654
Nusinersen
NXD-30001
Others
Global Spinal Muscular Atrophy Medicine Market, by Application, 2018-2023, 2024-2029 ($ Millions) & (K Pcs)
Global Spinal Muscular Atrophy Medicine Market Segment Percentages, by Application, 2022 (%)
Hospital
Clinic
Others
Global Spinal Muscular Atrophy Medicine Market, By Region and Country, 2018-2023, 2024-2029 ($ Millions) & (K Pcs)
Global Spinal Muscular Atrophy Medicine Market Segment Percentages, By Region and Country, 2022 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Spinal Muscular Atrophy Medicine revenues in global market, 2018-2023 (Estimated), ($ millions)
Key companies Spinal Muscular Atrophy Medicine revenues share in global market, 2022 (%)
Key companies Spinal Muscular Atrophy Medicine sales in global market, 2018-2023 (Estimated), (K Pcs)
Key companies Spinal Muscular Atrophy Medicine sales share in global market, 2022 (%)
Further, the report presents profiles of competitors in the market, key players include:
Astellas Pharma Inc.
AveXis, Inc.
Bioblast Pharma Ltd.
Cytokinetics, Inc. 24
F. Hoffmann-La Roche Ltd.
Genethon
Genzyme Corporation
GMP-Orphan SAS
Ionis Pharmaceuticals, Inc.
Longevity Biotech, Inc
Neurodyn Inc.
Neurotune AG
Novartis AG
Sarepta Therapeutics, Inc.
Voyager Therapeutics, Inc.
Vybion, Inc.
WAVE Life Sciences Ltd.
Outline of Major Chapters:
Chapter 1: Introduces the definition of Spinal Muscular Atrophy Medicine, market overview.
Chapter 2: Global Spinal Muscular Atrophy Medicine market size in revenue and volume.
Chapter 3: Detailed analysis of Spinal Muscular Atrophy Medicine manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Spinal Muscular Atrophy Medicine in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: Global Spinal Muscular Atrophy Medicine capacity by region & country.
Chapter 9: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 10: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 11: The main points and conclusions of the report.

❖ レポートの目次 ❖

1 Introduction to Research & Analysis Reports
1.1 Spinal Muscular Atrophy Medicine Market Definition
1.2 Market Segments
1.2.1 Market by Type
1.2.2 Market by Application
1.3 Global Spinal Muscular Atrophy Medicine Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
1.5.1 Research Methodology
1.5.2 Research Process
1.5.3 Base Year
1.5.4 Report Assumptions & Caveats
2 Global Spinal Muscular Atrophy Medicine Overall Market Size
2.1 Global Spinal Muscular Atrophy Medicine Market Size: 2022 VS 2029
2.2 Global Spinal Muscular Atrophy Medicine Revenue, Prospects & Forecasts: 2018-2029
2.3 Global Spinal Muscular Atrophy Medicine Sales: 2018-2029
3 Company Landscape
3.1 Top Spinal Muscular Atrophy Medicine Players in Global Market
3.2 Top Global Spinal Muscular Atrophy Medicine Companies Ranked by Revenue
3.3 Global Spinal Muscular Atrophy Medicine Revenue by Companies
3.4 Global Spinal Muscular Atrophy Medicine Sales by Companies
3.5 Global Spinal Muscular Atrophy Medicine Price by Manufacturer (2018-2023)
3.6 Top 3 and Top 5 Spinal Muscular Atrophy Medicine Companies in Global Market, by Revenue in 2022
3.7 Global Manufacturers Spinal Muscular Atrophy Medicine Product Type
3.8 Tier 1, Tier 2 and Tier 3 Spinal Muscular Atrophy Medicine Players in Global Market
3.8.1 List of Global Tier 1 Spinal Muscular Atrophy Medicine Companies
3.8.2 List of Global Tier 2 and Tier 3 Spinal Muscular Atrophy Medicine Companies
4 Sights by Product
4.1 Overview
4.1.1 By Type – Global Spinal Muscular Atrophy Medicine Market Size Markets, 2022 & 2029
4.1.2 LMI-070
4.1.3 ND-602
4.1.4 NT-1654
4.1.5 Nusinersen
4.1.6 NXD-30001
4.1.7 Others
4.2 By Type – Global Spinal Muscular Atrophy Medicine Revenue & Forecasts
4.2.1 By Type – Global Spinal Muscular Atrophy Medicine Revenue, 2018-2023
4.2.2 By Type – Global Spinal Muscular Atrophy Medicine Revenue, 2024-2029
4.2.3 By Type – Global Spinal Muscular Atrophy Medicine Revenue Market Share, 2018-2029
4.3 By Type – Global Spinal Muscular Atrophy Medicine Sales & Forecasts
4.3.1 By Type – Global Spinal Muscular Atrophy Medicine Sales, 2018-2023
4.3.2 By Type – Global Spinal Muscular Atrophy Medicine Sales, 2024-2029
4.3.3 By Type – Global Spinal Muscular Atrophy Medicine Sales Market Share, 2018-2029
4.4 By Type – Global Spinal Muscular Atrophy Medicine Price (Manufacturers Selling Prices), 2018-2029
5 Sights by Application
5.1 Overview
5.1.1 By Application – Global Spinal Muscular Atrophy Medicine Market Size, 2022 & 2029
5.1.2 Hospital
5.1.3 Clinic
5.1.4 Others
5.2 By Application – Global Spinal Muscular Atrophy Medicine Revenue & Forecasts
5.2.1 By Application – Global Spinal Muscular Atrophy Medicine Revenue, 2018-2023
5.2.2 By Application – Global Spinal Muscular Atrophy Medicine Revenue, 2024-2029
5.2.3 By Application – Global Spinal Muscular Atrophy Medicine Revenue Market Share, 2018-2029
5.3 By Application – Global Spinal Muscular Atrophy Medicine Sales & Forecasts
5.3.1 By Application – Global Spinal Muscular Atrophy Medicine Sales, 2018-2023
5.3.2 By Application – Global Spinal Muscular Atrophy Medicine Sales, 2024-2029
5.3.3 By Application – Global Spinal Muscular Atrophy Medicine Sales Market Share, 2018-2029
5.4 By Application – Global Spinal Muscular Atrophy Medicine Price (Manufacturers Selling Prices), 2018-2029
6 Sights by Region
6.1 By Region – Global Spinal Muscular Atrophy Medicine Market Size, 2022 & 2029
6.2 By Region – Global Spinal Muscular Atrophy Medicine Revenue & Forecasts
6.2.1 By Region – Global Spinal Muscular Atrophy Medicine Revenue, 2018-2023
6.2.2 By Region – Global Spinal Muscular Atrophy Medicine Revenue, 2024-2029
6.2.3 By Region – Global Spinal Muscular Atrophy Medicine Revenue Market Share, 2018-2029
6.3 By Region – Global Spinal Muscular Atrophy Medicine Sales & Forecasts
6.3.1 By Region – Global Spinal Muscular Atrophy Medicine Sales, 2018-2023
6.3.2 By Region – Global Spinal Muscular Atrophy Medicine Sales, 2024-2029
6.3.3 By Region – Global Spinal Muscular Atrophy Medicine Sales Market Share, 2018-2029
6.4 North America
6.4.1 By Country – North America Spinal Muscular Atrophy Medicine Revenue, 2018-2029
6.4.2 By Country – North America Spinal Muscular Atrophy Medicine Sales, 2018-2029
6.4.3 US Spinal Muscular Atrophy Medicine Market Size, 2018-2029
6.4.4 Canada Spinal Muscular Atrophy Medicine Market Size, 2018-2029
6.4.5 Mexico Spinal Muscular Atrophy Medicine Market Size, 2018-2029
6.5 Europe
6.5.1 By Country – Europe Spinal Muscular Atrophy Medicine Revenue, 2018-2029
6.5.2 By Country – Europe Spinal Muscular Atrophy Medicine Sales, 2018-2029
6.5.3 Germany Spinal Muscular Atrophy Medicine Market Size, 2018-2029
6.5.4 France Spinal Muscular Atrophy Medicine Market Size, 2018-2029
6.5.5 U.K. Spinal Muscular Atrophy Medicine Market Size, 2018-2029
6.5.6 Italy Spinal Muscular Atrophy Medicine Market Size, 2018-2029
6.5.7 Russia Spinal Muscular Atrophy Medicine Market Size, 2018-2029
6.5.8 Nordic Countries Spinal Muscular Atrophy Medicine Market Size, 2018-2029
6.5.9 Benelux Spinal Muscular Atrophy Medicine Market Size, 2018-2029
6.6 Asia
6.6.1 By Region – Asia Spinal Muscular Atrophy Medicine Revenue, 2018-2029
6.6.2 By Region – Asia Spinal Muscular Atrophy Medicine Sales, 2018-2029
6.6.3 China Spinal Muscular Atrophy Medicine Market Size, 2018-2029
6.6.4 Japan Spinal Muscular Atrophy Medicine Market Size, 2018-2029
6.6.5 South Korea Spinal Muscular Atrophy Medicine Market Size, 2018-2029
6.6.6 Southeast Asia Spinal Muscular Atrophy Medicine Market Size, 2018-2029
6.6.7 India Spinal Muscular Atrophy Medicine Market Size, 2018-2029
6.7 South America
6.7.1 By Country – South America Spinal Muscular Atrophy Medicine Revenue, 2018-2029
6.7.2 By Country – South America Spinal Muscular Atrophy Medicine Sales, 2018-2029
6.7.3 Brazil Spinal Muscular Atrophy Medicine Market Size, 2018-2029
6.7.4 Argentina Spinal Muscular Atrophy Medicine Market Size, 2018-2029
6.8 Middle East & Africa
6.8.1 By Country – Middle East & Africa Spinal Muscular Atrophy Medicine Revenue, 2018-2029
6.8.2 By Country – Middle East & Africa Spinal Muscular Atrophy Medicine Sales, 2018-2029
6.8.3 Turkey Spinal Muscular Atrophy Medicine Market Size, 2018-2029
6.8.4 Israel Spinal Muscular Atrophy Medicine Market Size, 2018-2029
6.8.5 Saudi Arabia Spinal Muscular Atrophy Medicine Market Size, 2018-2029
6.8.6 UAE Spinal Muscular Atrophy Medicine Market Size, 2018-2029
7 Manufacturers & Brands Profiles
7.1 Astellas Pharma Inc.
7.1.1 Astellas Pharma Inc. Company Summary
7.1.2 Astellas Pharma Inc. Business Overview
7.1.3 Astellas Pharma Inc. Spinal Muscular Atrophy Medicine Major Product Offerings
7.1.4 Astellas Pharma Inc. Spinal Muscular Atrophy Medicine Sales and Revenue in Global (2018-2023)
7.1.5 Astellas Pharma Inc. Key News & Latest Developments
7.2 AveXis, Inc.
7.2.1 AveXis, Inc. Company Summary
7.2.2 AveXis, Inc. Business Overview
7.2.3 AveXis, Inc. Spinal Muscular Atrophy Medicine Major Product Offerings
7.2.4 AveXis, Inc. Spinal Muscular Atrophy Medicine Sales and Revenue in Global (2018-2023)
7.2.5 AveXis, Inc. Key News & Latest Developments
7.3 Bioblast Pharma Ltd.
7.3.1 Bioblast Pharma Ltd. Company Summary
7.3.2 Bioblast Pharma Ltd. Business Overview
7.3.3 Bioblast Pharma Ltd. Spinal Muscular Atrophy Medicine Major Product Offerings
7.3.4 Bioblast Pharma Ltd. Spinal Muscular Atrophy Medicine Sales and Revenue in Global (2018-2023)
7.3.5 Bioblast Pharma Ltd. Key News & Latest Developments
7.4 Cytokinetics, Inc. 24
7.4.1 Cytokinetics, Inc. 24 Company Summary
7.4.2 Cytokinetics, Inc. 24 Business Overview
7.4.3 Cytokinetics, Inc. 24 Spinal Muscular Atrophy Medicine Major Product Offerings
7.4.4 Cytokinetics, Inc. 24 Spinal Muscular Atrophy Medicine Sales and Revenue in Global (2018-2023)
7.4.5 Cytokinetics, Inc. 24 Key News & Latest Developments
7.5 F. Hoffmann-La Roche Ltd.
7.5.1 F. Hoffmann-La Roche Ltd. Company Summary
7.5.2 F. Hoffmann-La Roche Ltd. Business Overview
7.5.3 F. Hoffmann-La Roche Ltd. Spinal Muscular Atrophy Medicine Major Product Offerings
7.5.4 F. Hoffmann-La Roche Ltd. Spinal Muscular Atrophy Medicine Sales and Revenue in Global (2018-2023)
7.5.5 F. Hoffmann-La Roche Ltd. Key News & Latest Developments
7.6 Genethon
7.6.1 Genethon Company Summary
7.6.2 Genethon Business Overview
7.6.3 Genethon Spinal Muscular Atrophy Medicine Major Product Offerings
7.6.4 Genethon Spinal Muscular Atrophy Medicine Sales and Revenue in Global (2018-2023)
7.6.5 Genethon Key News & Latest Developments
7.7 Genzyme Corporation
7.7.1 Genzyme Corporation Company Summary
7.7.2 Genzyme Corporation Business Overview
7.7.3 Genzyme Corporation Spinal Muscular Atrophy Medicine Major Product Offerings
7.7.4 Genzyme Corporation Spinal Muscular Atrophy Medicine Sales and Revenue in Global (2018-2023)
7.7.5 Genzyme Corporation Key News & Latest Developments
7.8 GMP-Orphan SAS
7.8.1 GMP-Orphan SAS Company Summary
7.8.2 GMP-Orphan SAS Business Overview
7.8.3 GMP-Orphan SAS Spinal Muscular Atrophy Medicine Major Product Offerings
7.8.4 GMP-Orphan SAS Spinal Muscular Atrophy Medicine Sales and Revenue in Global (2018-2023)
7.8.5 GMP-Orphan SAS Key News & Latest Developments
7.9 Ionis Pharmaceuticals, Inc.
7.9.1 Ionis Pharmaceuticals, Inc. Company Summary
7.9.2 Ionis Pharmaceuticals, Inc. Business Overview
7.9.3 Ionis Pharmaceuticals, Inc. Spinal Muscular Atrophy Medicine Major Product Offerings
7.9.4 Ionis Pharmaceuticals, Inc. Spinal Muscular Atrophy Medicine Sales and Revenue in Global (2018-2023)
7.9.5 Ionis Pharmaceuticals, Inc. Key News & Latest Developments
7.10 Longevity Biotech, Inc
7.10.1 Longevity Biotech, Inc Company Summary
7.10.2 Longevity Biotech, Inc Business Overview
7.10.3 Longevity Biotech, Inc Spinal Muscular Atrophy Medicine Major Product Offerings
7.10.4 Longevity Biotech, Inc Spinal Muscular Atrophy Medicine Sales and Revenue in Global (2018-2023)
7.10.5 Longevity Biotech, Inc Key News & Latest Developments
7.11 Neurodyn Inc.
7.11.1 Neurodyn Inc. Company Summary
7.11.2 Neurodyn Inc. Spinal Muscular Atrophy Medicine Business Overview
7.11.3 Neurodyn Inc. Spinal Muscular Atrophy Medicine Major Product Offerings
7.11.4 Neurodyn Inc. Spinal Muscular Atrophy Medicine Sales and Revenue in Global (2018-2023)
7.11.5 Neurodyn Inc. Key News & Latest Developments
7.12 Neurotune AG
7.12.1 Neurotune AG Company Summary
7.12.2 Neurotune AG Spinal Muscular Atrophy Medicine Business Overview
7.12.3 Neurotune AG Spinal Muscular Atrophy Medicine Major Product Offerings
7.12.4 Neurotune AG Spinal Muscular Atrophy Medicine Sales and Revenue in Global (2018-2023)
7.12.5 Neurotune AG Key News & Latest Developments
7.13 Novartis AG
7.13.1 Novartis AG Company Summary
7.13.2 Novartis AG Spinal Muscular Atrophy Medicine Business Overview
7.13.3 Novartis AG Spinal Muscular Atrophy Medicine Major Product Offerings
7.13.4 Novartis AG Spinal Muscular Atrophy Medicine Sales and Revenue in Global (2018-2023)
7.13.5 Novartis AG Key News & Latest Developments
7.14 Sarepta Therapeutics, Inc.
7.14.1 Sarepta Therapeutics, Inc. Company Summary
7.14.2 Sarepta Therapeutics, Inc. Business Overview
7.14.3 Sarepta Therapeutics, Inc. Spinal Muscular Atrophy Medicine Major Product Offerings
7.14.4 Sarepta Therapeutics, Inc. Spinal Muscular Atrophy Medicine Sales and Revenue in Global (2018-2023)
7.14.5 Sarepta Therapeutics, Inc. Key News & Latest Developments
7.15 Voyager Therapeutics, Inc.
7.15.1 Voyager Therapeutics, Inc. Company Summary
7.15.2 Voyager Therapeutics, Inc. Business Overview
7.15.3 Voyager Therapeutics, Inc. Spinal Muscular Atrophy Medicine Major Product Offerings
7.15.4 Voyager Therapeutics, Inc. Spinal Muscular Atrophy Medicine Sales and Revenue in Global (2018-2023)
7.15.5 Voyager Therapeutics, Inc. Key News & Latest Developments
7.16 Vybion, Inc.
7.16.1 Vybion, Inc. Company Summary
7.16.2 Vybion, Inc. Business Overview
7.16.3 Vybion, Inc. Spinal Muscular Atrophy Medicine Major Product Offerings
7.16.4 Vybion, Inc. Spinal Muscular Atrophy Medicine Sales and Revenue in Global (2018-2023)
7.16.5 Vybion, Inc. Key News & Latest Developments
7.17 WAVE Life Sciences Ltd.
7.17.1 WAVE Life Sciences Ltd. Company Summary
7.17.2 WAVE Life Sciences Ltd. Business Overview
7.17.3 WAVE Life Sciences Ltd. Spinal Muscular Atrophy Medicine Major Product Offerings
7.17.4 WAVE Life Sciences Ltd. Spinal Muscular Atrophy Medicine Sales and Revenue in Global (2018-2023)
7.17.5 WAVE Life Sciences Ltd. Key News & Latest Developments
8 Global Spinal Muscular Atrophy Medicine Production Capacity, Analysis
8.1 Global Spinal Muscular Atrophy Medicine Production Capacity, 2018-2029
8.2 Spinal Muscular Atrophy Medicine Production Capacity of Key Manufacturers in Global Market
8.3 Global Spinal Muscular Atrophy Medicine Production by Region
9 Key Market Trends, Opportunity, Drivers and Restraints
9.1 Market Opportunities & Trends
9.2 Market Drivers
9.3 Market Restraints
10 Spinal Muscular Atrophy Medicine Supply Chain Analysis
10.1 Spinal Muscular Atrophy Medicine Industry Value Chain
10.2 Spinal Muscular Atrophy Medicine Upstream Market
10.3 Spinal Muscular Atrophy Medicine Downstream and Clients
10.4 Marketing Channels Analysis
10.4.1 Marketing Channels
10.4.2 Spinal Muscular Atrophy Medicine Distributors and Sales Agents in Global
11 Conclusion
12 Appendix
12.1 Note
12.2 Examples of Clients
12.3 Disclaimer

List of Tables
Table 1. Key Players of Spinal Muscular Atrophy Medicine in Global Market
Table 2. Top Spinal Muscular Atrophy Medicine Players in Global Market, Ranking by Revenue (2022)
Table 3. Global Spinal Muscular Atrophy Medicine Revenue by Companies, (US$, Mn), 2018-2023
Table 4. Global Spinal Muscular Atrophy Medicine Revenue Share by Companies, 2018-2023
Table 5. Global Spinal Muscular Atrophy Medicine Sales by Companies, (K Pcs), 2018-2023
Table 6. Global Spinal Muscular Atrophy Medicine Sales Share by Companies, 2018-2023
Table 7. Key Manufacturers Spinal Muscular Atrophy Medicine Price (2018-2023) & (USD/Pcs)
Table 8. Global Manufacturers Spinal Muscular Atrophy Medicine Product Type
Table 9. List of Global Tier 1 Spinal Muscular Atrophy Medicine Companies, Revenue (US$, Mn) in 2022 and Market Share
Table 10. List of Global Tier 2 and Tier 3 Spinal Muscular Atrophy Medicine Companies, Revenue (US$, Mn) in 2022 and Market Share
Table 11. By Type – Global Spinal Muscular Atrophy Medicine Revenue, (US$, Mn), 2022 & 2029
Table 12. By Type - Global Spinal Muscular Atrophy Medicine Revenue (US$, Mn), 2018-2023
Table 13. By Type - Global Spinal Muscular Atrophy Medicine Revenue (US$, Mn), 2024-2029
Table 14. By Type - Global Spinal Muscular Atrophy Medicine Sales (K Pcs), 2018-2023
Table 15. By Type - Global Spinal Muscular Atrophy Medicine Sales (K Pcs), 2024-2029
Table 16. By Application – Global Spinal Muscular Atrophy Medicine Revenue, (US$, Mn), 2022 & 2029
Table 17. By Application - Global Spinal Muscular Atrophy Medicine Revenue (US$, Mn), 2018-2023
Table 18. By Application - Global Spinal Muscular Atrophy Medicine Revenue (US$, Mn), 2024-2029
Table 19. By Application - Global Spinal Muscular Atrophy Medicine Sales (K Pcs), 2018-2023
Table 20. By Application - Global Spinal Muscular Atrophy Medicine Sales (K Pcs), 2024-2029
Table 21. By Region – Global Spinal Muscular Atrophy Medicine Revenue, (US$, Mn), 2022 VS 2029
Table 22. By Region - Global Spinal Muscular Atrophy Medicine Revenue (US$, Mn), 2018-2023
Table 23. By Region - Global Spinal Muscular Atrophy Medicine Revenue (US$, Mn), 2024-2029
Table 24. By Region - Global Spinal Muscular Atrophy Medicine Sales (K Pcs), 2018-2023
Table 25. By Region - Global Spinal Muscular Atrophy Medicine Sales (K Pcs), 2024-2029
Table 26. By Country - North America Spinal Muscular Atrophy Medicine Revenue, (US$, Mn), 2018-2023
Table 27. By Country - North America Spinal Muscular Atrophy Medicine Revenue, (US$, Mn), 2024-2029
Table 28. By Country - North America Spinal Muscular Atrophy Medicine Sales, (K Pcs), 2018-2023
Table 29. By Country - North America Spinal Muscular Atrophy Medicine Sales, (K Pcs), 2024-2029
Table 30. By Country - Europe Spinal Muscular Atrophy Medicine Revenue, (US$, Mn), 2018-2023
Table 31. By Country - Europe Spinal Muscular Atrophy Medicine Revenue, (US$, Mn), 2024-2029
Table 32. By Country - Europe Spinal Muscular Atrophy Medicine Sales, (K Pcs), 2018-2023
Table 33. By Country - Europe Spinal Muscular Atrophy Medicine Sales, (K Pcs), 2024-2029
Table 34. By Region - Asia Spinal Muscular Atrophy Medicine Revenue, (US$, Mn), 2018-2023
Table 35. By Region - Asia Spinal Muscular Atrophy Medicine Revenue, (US$, Mn), 2024-2029
Table 36. By Region - Asia Spinal Muscular Atrophy Medicine Sales, (K Pcs), 2018-2023
Table 37. By Region - Asia Spinal Muscular Atrophy Medicine Sales, (K Pcs), 2024-2029
Table 38. By Country - South America Spinal Muscular Atrophy Medicine Revenue, (US$, Mn), 2018-2023
Table 39. By Country - South America Spinal Muscular Atrophy Medicine Revenue, (US$, Mn), 2024-2029
Table 40. By Country - South America Spinal Muscular Atrophy Medicine Sales, (K Pcs), 2018-2023
Table 41. By Country - South America Spinal Muscular Atrophy Medicine Sales, (K Pcs), 2024-2029
Table 42. By Country - Middle East & Africa Spinal Muscular Atrophy Medicine Revenue, (US$, Mn), 2018-2023
Table 43. By Country - Middle East & Africa Spinal Muscular Atrophy Medicine Revenue, (US$, Mn), 2024-2029
Table 44. By Country - Middle East & Africa Spinal Muscular Atrophy Medicine Sales, (K Pcs), 2018-2023
Table 45. By Country - Middle East & Africa Spinal Muscular Atrophy Medicine Sales, (K Pcs), 2024-2029
Table 46. Astellas Pharma Inc. Company Summary
Table 47. Astellas Pharma Inc. Spinal Muscular Atrophy Medicine Product Offerings
Table 48. Astellas Pharma Inc. Spinal Muscular Atrophy Medicine Sales (K Pcs), Revenue (US$, Mn) and Average Price (USD/Pcs) (2018-2023)
Table 49. Astellas Pharma Inc. Key News & Latest Developments
Table 50. AveXis, Inc. Company Summary
Table 51. AveXis, Inc. Spinal Muscular Atrophy Medicine Product Offerings
Table 52. AveXis, Inc. Spinal Muscular Atrophy Medicine Sales (K Pcs), Revenue (US$, Mn) and Average Price (USD/Pcs) (2018-2023)
Table 53. AveXis, Inc. Key News & Latest Developments
Table 54. Bioblast Pharma Ltd. Company Summary
Table 55. Bioblast Pharma Ltd. Spinal Muscular Atrophy Medicine Product Offerings
Table 56. Bioblast Pharma Ltd. Spinal Muscular Atrophy Medicine Sales (K Pcs), Revenue (US$, Mn) and Average Price (USD/Pcs) (2018-2023)
Table 57. Bioblast Pharma Ltd. Key News & Latest Developments
Table 58. Cytokinetics, Inc. 24 Company Summary
Table 59. Cytokinetics, Inc. 24 Spinal Muscular Atrophy Medicine Product Offerings
Table 60. Cytokinetics, Inc. 24 Spinal Muscular Atrophy Medicine Sales (K Pcs), Revenue (US$, Mn) and Average Price (USD/Pcs) (2018-2023)
Table 61. Cytokinetics, Inc. 24 Key News & Latest Developments
Table 62. F. Hoffmann-La Roche Ltd. Company Summary
Table 63. F. Hoffmann-La Roche Ltd. Spinal Muscular Atrophy Medicine Product Offerings
Table 64. F. Hoffmann-La Roche Ltd. Spinal Muscular Atrophy Medicine Sales (K Pcs), Revenue (US$, Mn) and Average Price (USD/Pcs) (2018-2023)
Table 65. F. Hoffmann-La Roche Ltd. Key News & Latest Developments
Table 66. Genethon Company Summary
Table 67. Genethon Spinal Muscular Atrophy Medicine Product Offerings
Table 68. Genethon Spinal Muscular Atrophy Medicine Sales (K Pcs), Revenue (US$, Mn) and Average Price (USD/Pcs) (2018-2023)
Table 69. Genethon Key News & Latest Developments
Table 70. Genzyme Corporation Company Summary
Table 71. Genzyme Corporation Spinal Muscular Atrophy Medicine Product Offerings
Table 72. Genzyme Corporation Spinal Muscular Atrophy Medicine Sales (K Pcs), Revenue (US$, Mn) and Average Price (USD/Pcs) (2018-2023)
Table 73. Genzyme Corporation Key News & Latest Developments
Table 74. GMP-Orphan SAS Company Summary
Table 75. GMP-Orphan SAS Spinal Muscular Atrophy Medicine Product Offerings
Table 76. GMP-Orphan SAS Spinal Muscular Atrophy Medicine Sales (K Pcs), Revenue (US$, Mn) and Average Price (USD/Pcs) (2018-2023)
Table 77. GMP-Orphan SAS Key News & Latest Developments
Table 78. Ionis Pharmaceuticals, Inc. Company Summary
Table 79. Ionis Pharmaceuticals, Inc. Spinal Muscular Atrophy Medicine Product Offerings
Table 80. Ionis Pharmaceuticals, Inc. Spinal Muscular Atrophy Medicine Sales (K Pcs), Revenue (US$, Mn) and Average Price (USD/Pcs) (2018-2023)
Table 81. Ionis Pharmaceuticals, Inc. Key News & Latest Developments
Table 82. Longevity Biotech, Inc Company Summary
Table 83. Longevity Biotech, Inc Spinal Muscular Atrophy Medicine Product Offerings
Table 84. Longevity Biotech, Inc Spinal Muscular Atrophy Medicine Sales (K Pcs), Revenue (US$, Mn) and Average Price (USD/Pcs) (2018-2023)
Table 85. Longevity Biotech, Inc Key News & Latest Developments
Table 86. Neurodyn Inc. Company Summary
Table 87. Neurodyn Inc. Spinal Muscular Atrophy Medicine Product Offerings
Table 88. Neurodyn Inc. Spinal Muscular Atrophy Medicine Sales (K Pcs), Revenue (US$, Mn) and Average Price (USD/Pcs) (2018-2023)
Table 89. Neurodyn Inc. Key News & Latest Developments
Table 90. Neurotune AG Company Summary
Table 91. Neurotune AG Spinal Muscular Atrophy Medicine Product Offerings
Table 92. Neurotune AG Spinal Muscular Atrophy Medicine Sales (K Pcs), Revenue (US$, Mn) and Average Price (USD/Pcs) (2018-2023)
Table 93. Neurotune AG Key News & Latest Developments
Table 94. Novartis AG Company Summary
Table 95. Novartis AG Spinal Muscular Atrophy Medicine Product Offerings
Table 96. Novartis AG Spinal Muscular Atrophy Medicine Sales (K Pcs), Revenue (US$, Mn) and Average Price (USD/Pcs) (2018-2023)
Table 97. Novartis AG Key News & Latest Developments
Table 98. Sarepta Therapeutics, Inc. Company Summary
Table 99. Sarepta Therapeutics, Inc. Spinal Muscular Atrophy Medicine Product Offerings
Table 100. Sarepta Therapeutics, Inc. Spinal Muscular Atrophy Medicine Sales (K Pcs), Revenue (US$, Mn) and Average Price (USD/Pcs) (2018-2023)
Table 101. Sarepta Therapeutics, Inc. Key News & Latest Developments
Table 102. Voyager Therapeutics, Inc. Company Summary
Table 103. Voyager Therapeutics, Inc. Spinal Muscular Atrophy Medicine Product Offerings
Table 104. Voyager Therapeutics, Inc. Spinal Muscular Atrophy Medicine Sales (K Pcs), Revenue (US$, Mn) and Average Price (USD/Pcs) (2018-2023)
Table 105. Voyager Therapeutics, Inc. Key News & Latest Developments
Table 106. Vybion, Inc. Company Summary
Table 107. Vybion, Inc. Spinal Muscular Atrophy Medicine Product Offerings
Table 108. Vybion, Inc. Spinal Muscular Atrophy Medicine Sales (K Pcs), Revenue (US$, Mn) and Average Price (USD/Pcs) (2018-2023)
Table 109. Vybion, Inc. Key News & Latest Developments
Table 110. WAVE Life Sciences Ltd. Company Summary
Table 111. WAVE Life Sciences Ltd. Spinal Muscular Atrophy Medicine Product Offerings
Table 112. WAVE Life Sciences Ltd. Spinal Muscular Atrophy Medicine Sales (K Pcs), Revenue (US$, Mn) and Average Price (USD/Pcs) (2018-2023)
Table 113. WAVE Life Sciences Ltd. Key News & Latest Developments
Table 114. Spinal Muscular Atrophy Medicine Production Capacity (K Pcs) of Key Manufacturers in Global Market, 2021-2023 (K Pcs)
Table 115. Global Spinal Muscular Atrophy Medicine Capacity Market Share of Key Manufacturers, 2021-2023
Table 116. Global Spinal Muscular Atrophy Medicine Production by Region, 2018-2023 (K Pcs)
Table 117. Global Spinal Muscular Atrophy Medicine Production by Region, 2024-2029 (K Pcs)
Table 118. Spinal Muscular Atrophy Medicine Market Opportunities & Trends in Global Market
Table 119. Spinal Muscular Atrophy Medicine Market Drivers in Global Market
Table 120. Spinal Muscular Atrophy Medicine Market Restraints in Global Market
Table 121. Spinal Muscular Atrophy Medicine Raw Materials
Table 122. Spinal Muscular Atrophy Medicine Raw Materials Suppliers in Global Market
Table 123. Typical Spinal Muscular Atrophy Medicine Downstream
Table 124. Spinal Muscular Atrophy Medicine Downstream Clients in Global Market
Table 125. Spinal Muscular Atrophy Medicine Distributors and Sales Agents in Global Market
List of Figures
Figure 1. Spinal Muscular Atrophy Medicine Segment by Type in 2022
Figure 2. Spinal Muscular Atrophy Medicine Segment by Application in 2022
Figure 3. Global Spinal Muscular Atrophy Medicine Market Overview: 2022
Figure 4. Key Caveats
Figure 5. Global Spinal Muscular Atrophy Medicine Market Size: 2022 VS 2029 (US$, Mn)
Figure 6. Global Spinal Muscular Atrophy Medicine Revenue, 2018-2029 (US$, Mn)
Figure 7. Spinal Muscular Atrophy Medicine Sales in Global Market: 2018-2029 (K Pcs)
Figure 8. The Top 3 and 5 Players Market Share by Spinal Muscular Atrophy Medicine Revenue in 2022
Figure 9. By Type - Global Spinal Muscular Atrophy Medicine Revenue, (US$, Mn), 2022 & 2029
Figure 10. By Type - Global Spinal Muscular Atrophy Medicine Revenue Market Share, 2018-2029
Figure 11. By Type - Global Spinal Muscular Atrophy Medicine Sales Market Share, 2018-2029
Figure 12. By Type - Global Spinal Muscular Atrophy Medicine Price (USD/Pcs), 2018-2029
Figure 13. By Application - Global Spinal Muscular Atrophy Medicine Revenue, (US$, Mn), 2022 & 2029
Figure 14. By Application - Global Spinal Muscular Atrophy Medicine Revenue Market Share, 2018-2029
Figure 15. By Application - Global Spinal Muscular Atrophy Medicine Sales Market Share, 2018-2029
Figure 16. By Application - Global Spinal Muscular Atrophy Medicine Price (USD/Pcs), 2018-2029
Figure 17. By Region - Global Spinal Muscular Atrophy Medicine Revenue, (US$, Mn), 2022 & 2029
Figure 18. By Region - Global Spinal Muscular Atrophy Medicine Revenue Market Share, 2018 VS 2022 VS 2029
Figure 19. By Region - Global Spinal Muscular Atrophy Medicine Revenue Market Share, 2018-2029
Figure 20. By Region - Global Spinal Muscular Atrophy Medicine Sales Market Share, 2018-2029
Figure 21. By Country - North America Spinal Muscular Atrophy Medicine Revenue Market Share, 2018-2029
Figure 22. By Country - North America Spinal Muscular Atrophy Medicine Sales Market Share, 2018-2029
Figure 23. US Spinal Muscular Atrophy Medicine Revenue, (US$, Mn), 2018-2029
Figure 24. Canada Spinal Muscular Atrophy Medicine Revenue, (US$, Mn), 2018-2029
Figure 25. Mexico Spinal Muscular Atrophy Medicine Revenue, (US$, Mn), 2018-2029
Figure 26. By Country - Europe Spinal Muscular Atrophy Medicine Revenue Market Share, 2018-2029
Figure 27. By Country - Europe Spinal Muscular Atrophy Medicine Sales Market Share, 2018-2029
Figure 28. Germany Spinal Muscular Atrophy Medicine Revenue, (US$, Mn), 2018-2029
Figure 29. France Spinal Muscular Atrophy Medicine Revenue, (US$, Mn), 2018-2029
Figure 30. U.K. Spinal Muscular Atrophy Medicine Revenue, (US$, Mn), 2018-2029
Figure 31. Italy Spinal Muscular Atrophy Medicine Revenue, (US$, Mn), 2018-2029
Figure 32. Russia Spinal Muscular Atrophy Medicine Revenue, (US$, Mn), 2018-2029
Figure 33. Nordic Countries Spinal Muscular Atrophy Medicine Revenue, (US$, Mn), 2018-2029
Figure 34. Benelux Spinal Muscular Atrophy Medicine Revenue, (US$, Mn), 2018-2029
Figure 35. By Region - Asia Spinal Muscular Atrophy Medicine Revenue Market Share, 2018-2029
Figure 36. By Region - Asia Spinal Muscular Atrophy Medicine Sales Market Share, 2018-2029
Figure 37. China Spinal Muscular Atrophy Medicine Revenue, (US$, Mn), 2018-2029
Figure 38. Japan Spinal Muscular Atrophy Medicine Revenue, (US$, Mn), 2018-2029
Figure 39. South Korea Spinal Muscular Atrophy Medicine Revenue, (US$, Mn), 2018-2029
Figure 40. Southeast Asia Spinal Muscular Atrophy Medicine Revenue, (US$, Mn), 2018-2029
Figure 41. India Spinal Muscular Atrophy Medicine Revenue, (US$, Mn), 2018-2029
Figure 42. By Country - South America Spinal Muscular Atrophy Medicine Revenue Market Share, 2018-2029
Figure 43. By Country - South America Spinal Muscular Atrophy Medicine Sales Market Share, 2018-2029
Figure 44. Brazil Spinal Muscular Atrophy Medicine Revenue, (US$, Mn), 2018-2029
Figure 45. Argentina Spinal Muscular Atrophy Medicine Revenue, (US$, Mn), 2018-2029
Figure 46. By Country - Middle East & Africa Spinal Muscular Atrophy Medicine Revenue Market Share, 2018-2029
Figure 47. By Country - Middle East & Africa Spinal Muscular Atrophy Medicine Sales Market Share, 2018-2029
Figure 48. Turkey Spinal Muscular Atrophy Medicine Revenue, (US$, Mn), 2018-2029
Figure 49. Israel Spinal Muscular Atrophy Medicine Revenue, (US$, Mn), 2018-2029
Figure 50. Saudi Arabia Spinal Muscular Atrophy Medicine Revenue, (US$, Mn), 2018-2029
Figure 51. UAE Spinal Muscular Atrophy Medicine Revenue, (US$, Mn), 2018-2029
Figure 52. Global Spinal Muscular Atrophy Medicine Production Capacity (K Pcs), 2018-2029
Figure 53. The Percentage of Production Spinal Muscular Atrophy Medicine by Region, 2022 VS 2029
Figure 54. Spinal Muscular Atrophy Medicine Industry Value Chain
Figure 55. Marketing Channels

❖ 免責事項 ❖
http://www.globalresearch.jp/disclaimer

★リサーチレポート[ 脊髄性筋萎縮症治療の世界市場見通し2023年-2029年(Spinal Muscular Atrophy Medicine Market, Global Outlook and Forecast 2023-2029)]についてメールでお問い合わせはこちらでお願いします。

GlobalResearch.jp

脊髄性筋萎縮症治療の世界市場見通し2023年-2029年

グローバル市場調査/マーケットリサーチ会社：レポート販売と委託調査サービス提供 www.GlobalResearch.jp